X hits on this document

43 views

0 shares

0 downloads

0 comments

17 / 19

Mark S. Luer, Pharm.D. page 17

Author, “Evaluation of Gastric pH Control in Head Trauma Patients by Continuous IV Infusion of Cimetidine.” FDA Annual Report for Investigational New Drug (IND). University of Kentucky College of Pharmacy. November 1992.

Editor, The Kentucky Connection, the newsletter of the University of Kentucky residency program. 1991.

XV. GRANT/CONTRACT ACTIVITY (Funded):

SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE Intramural 1. Web-based Assessment of Student Learning. SIUE Excellence in Undergraduate Education.

Co-Investigator, July 2007-June 2008. $5500

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES Extramural

  • 2.

    Blood Brain Barrier P-glycoprotein after Focal Ischemia: Implications for Selective Drug Delivery. American Heart Association – Heartland Affiliate. Principal Investigator, January 2003

    • December 2005. $121,000 (Indirect Costs: $11,000).

  • 3.

    CNS Mini-Sabbatical. American College of Clinical Pharmacy. July 2001 – June 2002. $2750

  • 4.

    Drug-Cytokine Interaction: IL-6 Impact on BBB Transport. American College of Clinical Pharmacy, Bristol-Myers Squibb Central Nervous System Research Award. Principal Investigator, July 1999 – December 2000. $10,000

  • 5.

    CNS Mini-Sabbatical. American College of Clinical Pharmacy. July 1999 – June 2000. $750

  • 6.

    Age-related Changes in BBB P-Glycoprotein Function. National Institute on Aging: Pilot Research Grant Program. Principal Investigator, January 1999 – December 1999. $72,927 (Indirect costs: $22,927) (RO3 AG16435-01)

  • 7.

    Age-related Changes in BBB P-Glycoprotein Function. AACP Young Investigators Award. Principal Investigator, January 1999 – December 1999. $12,500

  • 8.

    Anticonvulsant Activity of System-L Inhibition. Epilepsy Foundation of America (EFA). Principal Investigator, July 1997 - June 1998. $39,985.47

  • 9.

    Competitive Inhibition of Gabapentin Brain Uptake in the Rat. American College of Clinical Pharmacy, Bristol-Myers Squibb Central Nervous System Research Award. Principal Investigator, July 1997 - June 1998. $10,000

Intramural

  • 10.

    The Role of P-glycoprotein in Alzheimer’s Disease. Veteran’s Administration Biomedical Research Foundation. Co-Investigator. January 2003 – December 2003. $40,000

  • 11.

    Evaluation of cGMP Dependent Alterations in Cerebral Blood Flow in Alzheimer’s Disease. NIH - UAMS Alzheimer’s Disease Clinical Core (ADCC) Dementia Pilot Research Program. Principal Investigator, January 2002 – June 2004. $20,000

  • 12.

    Acute Phase Response and BBB P-Glycoprotein Function. UAMS Medical Research Endowment Award. Principal Investigator, January 1999 – December 1999. $14,998

UNIVERSITY OF ILLINOIS CHICAGO Extramural

  • 13.

    Stability of Fosphenytoin in Common Intravenous Fluid Admixtures and Containers. Parke- Davis Pharmaceuticals, Division of Warner-Lambert Company. Co-Investigator, January 1996. $35,325.90

  • 14.

    Pharmacokinetics and Antibacterial Efficacy of Rifabutin in Cerebrospinal Fluid. Pharmacia Pharmaceutical Company. Principal Investigator, January 1995. $25,000

  • 15.

    A Double-blind, Randomized Parallel-Group, Single-dose, Multicenter, Safety, Tolerance, and Pharmacokinetic Study of Intravenous Fosphenytoin (Cerebyx®) Versus Intravenous Dilantin® in Patients Requiring a Loading Dose of Phenytoin. Parke-Davis Pharmaceuticals, Division of Warner-Lambert Company. Co-Investigator, 1995. $112,000

Document info
Document views43
Page views43
Page last viewedSun Dec 04 20:18:52 UTC 2016
Pages19
Paragraphs522
Words6688

Comments